Atopic Dermatitis Market Growth Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 16 2026
0mins
Should l Buy AMGN?
Source: Newsfilter
- Market Size Growth: The atopic dermatitis treatment market is expected to continue growing positively by 2034, with the United States holding the largest market share, reflecting strong demand for new therapies that drive overall market expansion.
- Introduction of New Therapies: The launch of new therapies such as Rocatinlimab and Amlitelimab is anticipated to transform the market landscape by providing more effective treatment options to meet the increasing patient demand.
- Rising Patient Numbers: In 2024, approximately 53 million diagnosed cases of atopic dermatitis are expected in the 7MM, with the increase in patient numbers directly fueling the demand for advanced treatment options and promoting market growth.
- Changing Competitive Landscape: As new drugs undergo clinical trials and enter the market, competition will intensify, particularly with companies like Eli Lilly leveraging their product portfolios to capture significant market share in the EU4 and Japan, showcasing strong market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to fall
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 388.160
Low
280.00
Averages
363.10
High
425.00
Current: 388.160
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Couple's Financial Manifesto Revisited and Market Insights
- Dow Jones Milestone: On February 6, 2026, the Dow Jones Industrial Average surpassed 50,000 for the first time, marking a 25% increase from 40,000 less than two years ago, outperforming both the S&P 500 and NASDAQ, which reflects a resurgence of investor confidence and stability in turbulent economic times.
- Mixed Job Market Signals: The U.S. Bureau of Labor Statistics reported a 130,000 increase in non-farm payrolls for January, more than double the expected 60,000, with the unemployment rate dropping to 4.3%; however, most new jobs were concentrated in healthcare and social assistance, indicating an uneven economic recovery.
- Rising Government Debt: The Congressional Budget Office projects that the U.S. government will overspend by $5.8 trillion in 2026, with this figure expected to rise to $6 trillion by 2036, pushing federal debt to 120% of GDP, which poses significant challenges to fiscal sustainability and long-term economic health.
- Importance of Financial Management: Robert and Elizabeth Brokamp discussed their financial manifesto created 26 years ago, emphasizing the necessity of regular financial check-ins to prevent marital discord due to financial disagreements, highlighting the critical role of effective financial communication in maintaining family harmony.
See More
Revisiting the Couple's Financial Manifesto
- Dow Jones Milestone: On February 6, 2026, the Dow Jones Industrial Average surpassed 50,000 for the first time, marking a 25% increase from 40,000 less than two years ago, indicating strong recent performance driven by high allocations in industrials and energy sectors.
- Job Market Signals: The U.S. Bureau of Labor Statistics reported a 130,000 increase in non-farm payrolls for January 2026, more than double the expected 60,000, with the unemployment rate dropping to 4.3%, reflecting positive economic recovery signals, although most new jobs were in healthcare and social assistance.
- Government Deficit: According to the Congressional Budget Office, the U.S. government will spend $5.8 trillion more than it collects in taxes and tariffs in 2026, with projections indicating this annual deficit could rise to $6 trillion by 2036, highlighting ongoing fiscal pressures and reliance on borrowing.
- Importance of Financial Planning: Robert and Elizabeth Brokamp discussed their financial manifesto created 26 years ago, emphasizing the need for regular check-ins on financial goals and priorities to prevent financial disagreements that can lead to marital discord.
See More
Amgen Inc. Shows Bullish Outlook with Strong Fundamentals
- Stock Performance: As of February 23, 2026, Amgen Inc. (AMGN) shares traded at $376, reflecting a 36.41% appreciation since our last coverage in May 2025, indicating strong market confidence and growth potential.
- Financial Metrics: With trailing and forward P/E ratios of 24.32 and 13.74 respectively, alongside projected 2026 revenues of approximately $38.4 billion, Amgen demonstrates compelling growth prospects in the biotech sector.
- Options Market Signal: A trader sold 1,000 June 18, 2026 $340 put contracts for $9.00 each, collecting $900,000 in upfront premium, reflecting market confidence in Amgen's future performance.
- Cash Flow and Dividends: Amgen boasts around $9.1 billion in cash and a 2.6% dividend yield, enhancing its financial stability while providing funding support for future growth.
See More
VivaVision Races for Hong Kong IPO to Sustain Cash Flow
- Clinical Trial Progress: VivaVision's two drugs have reached Phase Three clinical trials, with one receiving regulatory fast track designation as a breakthrough therapy for eye inflammation, indicating its potential in the ophthalmic treatment sector.
- Increasing Financial Pressure: As of September 2025, the company had only 35.77 million yuan ($5.2 million) in cash, while net losses for the first three quarters of 2025 reached 131 million yuan, averaging about 43.33 million yuan per quarter, compelling the company to list quickly to replenish its funds.
- Funding History: Over its funding rounds, VivaVision has raised approximately 735 million yuan, with its valuation soaring from 17 million yuan to nearly 1.83 billion yuan, reflecting investor confidence in its long-term potential for innovative eye care solutions.
- Intense Market Competition: Despite advancements in eye inflammation treatment, the dry eye therapy market is highly competitive, with five innovative drugs already approved in China and another ten candidates at Phase Two or beyond, posing significant commercialization challenges.
See More
Novo Nordisk Faces Market Pressures and Competition
- Market Share Decline: Despite being the first to launch a GLP-1 weight loss drug, Novo Nordisk's market share has fallen to about 40%, while rival Eli Lilly holds 60%, indicating a significant competitive disadvantage that could hinder future growth potential.
- Sales Forecast Downgrade: Novo Nordisk anticipates a 5% to 13% decline in sales and profits for 2026, marking the first annual sales drop since 2017, reflecting the company's vulnerability amid fierce competition and pricing pressures, which may further erode investor confidence.
- Drug Development Challenges: The disappointing trial results of Novo's next-generation weight loss drug CagriSema against Eli Lilly's Zepbound led to a more than 16% drop in stock price on the day of the announcement, significantly diminishing analysts' confidence in its commercial potential and possibly affecting future market performance.
- Increasing Pricing Pressure: The decline in GLP-1 drug prices in the U.S. is weighing on Novo Nordisk's revenue and profitability, especially since the U.S. market has accounted for over half of its total sales since 2023, making future pricing strategies critical for the company's ability to regain growth.
See More
Eli Lilly's Dominance in Obesity Drug Market Reinforced
- Clinical Trial Comparison: Eli Lilly's Zepbound demonstrated superior efficacy in a head-to-head trial, with participants losing an average of 25.5% of their body weight compared to Novo Nordisk's CagriSema at 23%, reinforcing Lilly's leadership in obesity drug effectiveness and solidifying its market position.
- New Device Launch: Lilly introduced a new Zepbound injection device in the U.S. that provides a month's supply, enhancing patient convenience; while the immediate financial impact may be limited, it showcases Lilly's supply chain advantages and commitment to patient care.
- Significant Market Reaction: Following disappointing trial results, Novo Nordisk's shares fell over 15%, while Lilly's stock rose more than 4%, reflecting investor confidence in Lilly's growth potential and widening the gap between the two companies in the market.
- Future Development Potential: Lilly is advancing multiple next-generation obesity treatments, including retatrutide and eloralintide, targeting appetite-related hormones, with analysts noting that Lilly's competitive edge is expanding, positioning the company for further market leadership in the obesity drug sector.
See More
Couple's Financial Manifesto Revisited and Market Insights
- Dow Jones Milestone: On February 6, 2026, the Dow Jones Industrial Average surpassed 50,000 for the first time, marking a 25% increase from 40,000 less than two years ago, outperforming both the S&P 500 and NASDAQ, which reflects a resurgence of investor confidence and stability in turbulent economic times.
- Mixed Job Market Signals: The U.S. Bureau of Labor Statistics reported a 130,000 increase in non-farm payrolls for January, more than double the expected 60,000, with the unemployment rate dropping to 4.3%; however, most new jobs were concentrated in healthcare and social assistance, indicating an uneven economic recovery.
- Rising Government Debt: The Congressional Budget Office projects that the U.S. government will overspend by $5.8 trillion in 2026, with this figure expected to rise to $6 trillion by 2036, pushing federal debt to 120% of GDP, which poses significant challenges to fiscal sustainability and long-term economic health.
- Importance of Financial Management: Robert and Elizabeth Brokamp discussed their financial manifesto created 26 years ago, emphasizing the necessity of regular financial check-ins to prevent marital discord due to financial disagreements, highlighting the critical role of effective financial communication in maintaining family harmony.
See More
Revisiting the Couple's Financial Manifesto
- Dow Jones Milestone: On February 6, 2026, the Dow Jones Industrial Average surpassed 50,000 for the first time, marking a 25% increase from 40,000 less than two years ago, indicating strong recent performance driven by high allocations in industrials and energy sectors.
- Job Market Signals: The U.S. Bureau of Labor Statistics reported a 130,000 increase in non-farm payrolls for January 2026, more than double the expected 60,000, with the unemployment rate dropping to 4.3%, reflecting positive economic recovery signals, although most new jobs were in healthcare and social assistance.
- Government Deficit: According to the Congressional Budget Office, the U.S. government will spend $5.8 trillion more than it collects in taxes and tariffs in 2026, with projections indicating this annual deficit could rise to $6 trillion by 2036, highlighting ongoing fiscal pressures and reliance on borrowing.
- Importance of Financial Planning: Robert and Elizabeth Brokamp discussed their financial manifesto created 26 years ago, emphasizing the need for regular check-ins on financial goals and priorities to prevent financial disagreements that can lead to marital discord.
See More
Amgen Inc. Shows Bullish Outlook with Strong Fundamentals
- Stock Performance: As of February 23, 2026, Amgen Inc. (AMGN) shares traded at $376, reflecting a 36.41% appreciation since our last coverage in May 2025, indicating strong market confidence and growth potential.
- Financial Metrics: With trailing and forward P/E ratios of 24.32 and 13.74 respectively, alongside projected 2026 revenues of approximately $38.4 billion, Amgen demonstrates compelling growth prospects in the biotech sector.
- Options Market Signal: A trader sold 1,000 June 18, 2026 $340 put contracts for $9.00 each, collecting $900,000 in upfront premium, reflecting market confidence in Amgen's future performance.
- Cash Flow and Dividends: Amgen boasts around $9.1 billion in cash and a 2.6% dividend yield, enhancing its financial stability while providing funding support for future growth.
See More
VivaVision Races for Hong Kong IPO to Sustain Cash Flow
- Clinical Trial Progress: VivaVision's two drugs have reached Phase Three clinical trials, with one receiving regulatory fast track designation as a breakthrough therapy for eye inflammation, indicating its potential in the ophthalmic treatment sector.
- Increasing Financial Pressure: As of September 2025, the company had only 35.77 million yuan ($5.2 million) in cash, while net losses for the first three quarters of 2025 reached 131 million yuan, averaging about 43.33 million yuan per quarter, compelling the company to list quickly to replenish its funds.
- Funding History: Over its funding rounds, VivaVision has raised approximately 735 million yuan, with its valuation soaring from 17 million yuan to nearly 1.83 billion yuan, reflecting investor confidence in its long-term potential for innovative eye care solutions.
- Intense Market Competition: Despite advancements in eye inflammation treatment, the dry eye therapy market is highly competitive, with five innovative drugs already approved in China and another ten candidates at Phase Two or beyond, posing significant commercialization challenges.
See More
Novo Nordisk Faces Market Pressures and Competition
- Market Share Decline: Despite being the first to launch a GLP-1 weight loss drug, Novo Nordisk's market share has fallen to about 40%, while rival Eli Lilly holds 60%, indicating a significant competitive disadvantage that could hinder future growth potential.
- Sales Forecast Downgrade: Novo Nordisk anticipates a 5% to 13% decline in sales and profits for 2026, marking the first annual sales drop since 2017, reflecting the company's vulnerability amid fierce competition and pricing pressures, which may further erode investor confidence.
- Drug Development Challenges: The disappointing trial results of Novo's next-generation weight loss drug CagriSema against Eli Lilly's Zepbound led to a more than 16% drop in stock price on the day of the announcement, significantly diminishing analysts' confidence in its commercial potential and possibly affecting future market performance.
- Increasing Pricing Pressure: The decline in GLP-1 drug prices in the U.S. is weighing on Novo Nordisk's revenue and profitability, especially since the U.S. market has accounted for over half of its total sales since 2023, making future pricing strategies critical for the company's ability to regain growth.
See More
Eli Lilly's Dominance in Obesity Drug Market Reinforced
- Clinical Trial Comparison: Eli Lilly's Zepbound demonstrated superior efficacy in a head-to-head trial, with participants losing an average of 25.5% of their body weight compared to Novo Nordisk's CagriSema at 23%, reinforcing Lilly's leadership in obesity drug effectiveness and solidifying its market position.
- New Device Launch: Lilly introduced a new Zepbound injection device in the U.S. that provides a month's supply, enhancing patient convenience; while the immediate financial impact may be limited, it showcases Lilly's supply chain advantages and commitment to patient care.
- Significant Market Reaction: Following disappointing trial results, Novo Nordisk's shares fell over 15%, while Lilly's stock rose more than 4%, reflecting investor confidence in Lilly's growth potential and widening the gap between the two companies in the market.
- Future Development Potential: Lilly is advancing multiple next-generation obesity treatments, including retatrutide and eloralintide, targeting appetite-related hormones, with analysts noting that Lilly's competitive edge is expanding, positioning the company for further market leadership in the obesity drug sector.
See More
